Dicerna Reports Second Quarter 2016 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Dicerna Pharma (DRNA) Tops Q2 EPS by 9c
August 4, 2016 4:43 PM EDTDicerna Pharma (NASDAQ: DRNA) reported Q2 EPS of ($0.75), $0.09 better than the analyst estimate of ($0.84).
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
... More